

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 January 2025 (23.01.2025)



(10) International Publication Number
WO 2025/019318 A2

(51) International Patent Classification:
A61K 31/504 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2024/037809

(22) International Filing Date:
12 July 2024 (12.07.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/526,781 14 July 2023 (14.07.2023) US
63/618,731 08 January 2024 (08.01.2024) US

(71) Applicant: **REVOLUTION MEDICINES, INC.**
[US/US]; 700 Saginaw Drive, Redwood City, CA 94063 (US).

(72) Inventors: **JIANG, Jingjing**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **MALDONATO, Ben**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **SALMAN, Zeena**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **SINGH, Mallika**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **WANG, Zhengping**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **CHANG, Stephanie, S.**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **GUSTAFSON, W., Clay**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US).

(74) Agent: **BELLIVEAU, Michael, J.** et al.; Clark & Elbing LLP, 101 Federal Street, 15th Floor, Boston, MA 02110 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

(54) Title: METHODS OF TREATING A RAS RELATED DISEASE OR DISORDER



(57) Abstract: The disclosure features methods of treating RAS disorders using safe and effective doses of Compound (A), or a pharmaceutically acceptable salt thereof. The disclosure also features methods of treating RAS disorders including combination therapies comprising Compound (A), or a pharmaceutically acceptable salt thereof, and additional therapeutic agent.

WO 2025/019318 A2